LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global esophageal cancer drugs market and the market is poised to grow by USD 1.5 billion during 2019-2023 at a CAGR of over 8% during the forecast period. Request Free Sample Pages
Read the 118-page research report with TOC on "Esophageal Cancer Drugs Market Analysis Report by Product (Targeted therapy and Chemotherapy), by Type (Adenocarcinoma and Squamous cell carcinoma), and Segment Forecasts, 2019 - 2023".
The market is driven by the availability of favorable reimbursements. In addition, the use of multimodality treatment approach is anticipated to further boost the growth of the esophageal cancer drugs market.
Based on the cancer subtypes and adverse drug reactions, physicians prescribe standard chemotherapy regimens in combinations with other drugs. Favorable reimbursement for esophageal cancer, especially in developed countries is essential to ensure patient access to the available therapeutics. For instance, a federal government program in the US provides policies including Medicare Part A (hospital insurance) and Medicare Part B (medical insurance) to cover chemotherapy for cancer patients. Similarly, the Ministry of Health and Long-Term Care in Canada has been providing funds for CYRAMZA through the Cancer Ontario’s New Drug Funding Program since October 2015. Thus, the availability of reimbursements is expected to drive market growth during the forecast period.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing
Major Five Esophageal Cancer Drugs Market Companies:
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company is headquartered in the US and operates the business under the segment Biopharmaceuticals. The company offers ETOPOPHOS and TAXOL to various end-users.
Eli Lilly and Company
Eli Lilly and Company is headquartered in the US and offers products through the following business units: Human pharmaceutical products and Animal health products. The company offers CYRAMZA, which is prescribed for the treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma.
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd is headquartered in Switzerland and operates under two business segments, namely Pharmaceuticals and Diagnostics. The company offers Herceptin for the treatment of patients with HER2-overexpressing metastatic gastric.
Merck & Co., Inc.
Merck & Co., Inc. is headquartered in the US and offers products through the following business segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers KEYTRUDA for the treatment of patients with programmed death-ligand 1 (PD-L1)-positive gastroesophageal cancer.
Sanofi is headquartered in France and offers products through the following business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company offers TAXOTERE for the treatment of gastroesophageal junction adenocarcinoma.
Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform
Esophageal Cancer Drugs Product Outlook (Revenue, USD Million, 2019 - 2023)
- Targeted therapy
Esophageal Cancer Drugs Regional Outlook (Revenue, USD Million, 2019 - 2023)
- North America
Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report
Related Reports on Health Care include:
Cancer Biologics Market – Global Cancer Biologics Market by product (monoclonal antibodies, vaccines, cell and gene therapy, and others) and geography (Asia, Europe, North America, and ROW).
Bone Cancer Drugs Market – Global Bone Cancer Drugs Market by indication (osteosarcoma, Ewing’s sarcoma, chondrosarcoma, and others) and geography (Asia, Europe, North America, and ROW).
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.